Metabolic-associated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome: a matched case–control study
Authors:
- 9 October 2021
- journal article
- research article
- Published by Springer Nature in Hepatology International
- Vol. 15 (6) , 1337-1346
Abstract
Background and aims A consensus of experts suggests that nonalcoholic fatty liver disease (NAFLD) does not appropriately reflect current knowledge and metabolic-associated fatty liver disease (MAFLD) is supposed to be a more suitable overarching concept. However, the association of MAFLD with cardiovascular outcomes in patients with coronary artery disease has not been examined yet. Thus, this study aimed to assess the impact of MAFLD on major adverse cardiac events (MACEs) in patients with chronic coronary syndrome (CCS). Methods This study included 3306 patients with CCS who were diagnosed with MAFLD. Controls without MAFLD were matched (1:1) to cases by age and gender. All participants were followed up for the occurrence of MACEs. Finally, the association between MAFLD and the risk of MACEs was assessed. Results During an average of 55.09 ± 19.92 months follow-up, 376 and 248 MACEs were observed in MAFLD and control groups, respectively. When compared with controls, Kaplan–Meier analysis showed that patients with MAFLD had significantly lower event-free survival rate and multivariate Cox regression analysis further revealed that MAFLD group had significantly increased MACEs risk (both p < 0.05). Stratification analysis suggested that patients with MAFLD overlapped with NAFLD or MAFLD-only had 1.33-fold and 2.32-fold higher risk of MACEs respectively compared with controls (both p < 0.05). Conclusion This study firstly showed that MAFLD was significantly associated with the risk of MACEs in patients with CCS. Moreover, this relationship remained unchanged irrespective of whether satisfying the NAFLD criteria, providing novel evidence for the good utility of MAFLD criteria in clinical practice. Graphic abstractKeywords
Funding Information
- the Capital Health Development Fund (201614035)
- CAMS Major Collaborative Innovation Project (2016-I2M-1-011)
- Fundamental Research Funds for the Central Universities (2019-XHQN09)
- the youth research fund of peking union medical college (2019-F11)
This publication has 27 references indexed in Scilit:
- MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver DiseaseGastroenterology, 2020
- 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromesEuropean Heart Journal, 2019
- NASH in Lean IndividualsSeminars in Liver Disease, 2019
- Global burden of NAFLD and NASH: trends, predictions, risk factors and preventionNature Reviews Gastroenterology & Hepatology, 2017
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver diseaseJournal of Hepatology, 2016
- Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomesHepatology, 2015
- NAFLD: A multisystem diseaseJournal of Hepatology, 2015
- Editorial: Noninvasive Prediction of Hepatic SteatosisAmerican Journal of Gastroenterology, 2014
- Development, External Validation, and Comparative Assessment of a New Diagnostic Score for Hepatic SteatosisAmerican Journal of Gastroenterology, 2014
- Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver diseaseDigestive and Liver Disease, 2010